10-Q
Quarterly Report
AGENUS INC
AGEN
NASDAQ
CIK: 1098972
File #: 000-29089
Balance Sheet
43 line items · 2 periods
XBRL
| Item | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|
ASSETS | ||
Cash and cash equivalents | 52,856,000 | 76,110,000 |
MiNK Therapeutics, Inc. | — | 3,400,000 |
Accounts receivable | 476,000 | 25,836,000 |
Prepaid expenses | 3,895,000 | 8,098,000 |
Other current assets | 3,125,000 | 2,372,000 |
Total current assets | 60,352,000 | 112,416,000 |
Property, plant and equipment, net of accumulated amortization and depreciation of $65,080 and $61,943 at March 31, 2024 and December 31, 2023, respectively | 130,330,000 | 133,421,000 |
Operating lease right-of-use assets | 29,340,000 | 29,606,000 |
Goodwill | 24,698,000 | 24,723,000 |
Acquired intangible assets, net of accumulated amortization of $17,799 and $17,688 at March 31, 2024 and December 31, 2023, respectively | 4,230,000 | 4,411,000 |
Other long-term assets | 7,609,000 | 9,336,000 |
Total assets | 256,559,000 | 313,913,000 |
LIABILITIES AND STOCKHOLDERS' DEFICIT | ||
Current portion, long-term debt | 13,575,000 | 146,000 |
Current portion, liability related to sale of future royalties and milestones | 133,588,000 | 132,502,000 |
Current portion, deferred revenue | 13,000 | 18,000 |
Current portion, operating lease liabilities | 2,811,000 | 2,587,000 |
Accounts payable | 50,693,000 | 61,446,000 |
Accrued liabilities | 41,291,000 | 45,283,000 |
Other current liabilities | 14,031,000 | 13,915,000 |
Total current liabilities | 256,002,000 | 255,897,000 |
Long-term debt, net of current portion | 0 | 12,768,000 |
Liability related to sale of future royalties and milestones, net of current portion | 125,249,000 | 124,556,000 |
Deferred revenue, net of current portion | 1,143,000 | 1,143,000 |
Operating lease liabilities, net of current portion | 61,756,000 | 62,511,000 |
Other long-term liabilities | 2,732,000 | 5,420,000 |
STOCKHOLDERS" DEFICIT | ||
Series A-1 convertible preferred stock | 0 | 0 |
Common stock, par value $0.01 per share; 800,000,000 shares authorized; 20,994,143 and 19,718,662 shares issued at March 31, 2024 and December 31, 2023, respectively | 210,000 | 197,000 |
Additional paid-in capital | 1,816,985,000 | 1,796,095,000 |
Accumulated other comprehensive loss | (1,071,000) | (955,000) |
Accumulated deficit | (2,017,554,000) | (1,955,668,000) |
Total stockholders' deficit attributable to Agenus Inc. | (201,430,000) | (160,331,000) |
Non-controlling interest | 11,107,000 | 11,949,000 |
Non-controlling Interest | 11,107,000 | 11,949,000 |
Total stockholders' deficit | (190,323,000) | (148,382,000) |
Accumulated Other Comprehensive Income (Loss) | (1,071,000) | (955,000) |
Additional Paid-in Capital | 1,816,985,000 | 1,796,095,000 |
Accumulated Deficit | (2,017,554,000) | (1,955,668,000) |
Non-controlling Interest | 11,107,000 | 11,949,000 |
Common Stock | 210,000 | 197,000 |
Total liabilities and stockholders' deficit | 256,559,000 | 313,913,000 |